Hendley & Co. Inc. Makes New $11.37 Million Investment in AstraZeneca PLC $AZNCF

Hendley & Co. Inc. bought a new position in shares of AstraZeneca PLC (OTCMKTS:AZNCF) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 64,805 shares of the company’s stock, valued at approximately $11,373,000. AstraZeneca makes up 4.0% of Hendley & Co. Inc.’s investment portfolio, making the stock its 9th biggest holding.

A number of other institutional investors also recently bought and sold shares of the company. Valley Wealth Managers Inc. purchased a new stake in AstraZeneca during the fourth quarter worth $144,000. Mascoma Wealth Management LLC purchased a new stake in AstraZeneca during the fourth quarter worth $46,000. Saranac Partners Ltd purchased a new stake in AstraZeneca during the third quarter worth $876,000. Finally, Boston Common Asset Management LLC boosted its position in AstraZeneca by 5.6% during the third quarter. Boston Common Asset Management LLC now owns 192,589 shares of the company’s stock worth $28,992,000 after purchasing an additional 10,154 shares in the last quarter. 40.87% of the stock is currently owned by hedge funds and other institutional investors.

AstraZeneca Stock Performance

AZNCF opened at $187.10 on Friday. The business’s fifty day moving average is $187.10 and its two-hundred day moving average is $183.70. AstraZeneca PLC has a one year low of $122.26 and a one year high of $195.00.

AstraZeneca Company Profile

AstraZeneca (OTCMKTS:AZNCF) is a global biopharmaceutical company that focuses on the discovery, development, manufacturing and commercialization of prescription medicines. The company’s research and development efforts are concentrated in three main therapeutic areas: oncology; cardiovascular, renal and metabolism; and respiratory, inflammation and autoimmunity. AstraZeneca’s product portfolio includes targeted therapies for lung and breast cancers, novel agents for heart failure and chronic kidney disease, and inhaled treatments for asthma and chronic obstructive pulmonary disease.

The company was formed in 1999 through the merger of Sweden’s Astra AB and the United Kingdom’s Zeneca Group, creating one of the world’s largest pharmaceutical firms.